The American company "Pfizer" and the German "Biontech" announced, today, Wednesday, that the results of clinical tests of their vaccine against the emerging corona virus indicate its success in confronting the virus by 95%.
In a statement published by "Pfizer", the American company said that it and "Biontech" announced, earlier in the day, that the recent analysis of the effectiveness of the "BNT162b2" vaccine, which they developed together, showed that its effectiveness is 95%, after 28 days after the injection First.
The statement indicated that the two companies will apply to the US Food and Drug Administration in the coming days, to obtain an official license for their vaccine in the United States.
On the ninth of November, the "Pfizer" pharmaceutical industries announced that its vaccine, which it had developed in partnership with German Biontech, had proven effective by more than 90%, during the third phase of clinical trials.
Pfizer's announcement marked the first believable victory over the pandemic that has gripped the world since late last year. The American company expected that its vaccine would lead the global vaccine race against the emerging corona virus.
Five days after Pfizer announced the vaccine that moved global financial markets, the American company "Moderna" announced, on November 16, that its experimental vaccine showed an effectiveness of 94.5%.
The company said these are early results of a clinical test on more than 30,000 participants.
Moderna CEO Stephan Bancel said: "This positive interim analysis of our Phase III study gave us the first clinical evidence that our vaccine is able to prevent Covid-19 disease, including severe disease."
Despite the promising results of the Moderna vaccine, Pfizer's precedence in announcing the success of its vaccine gave him wide fame and prompted many countries to try to conclude agreements to obtain it.
0 Comments